NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Circe Biotechnologie GmbH

Circe Biotechnologie GmbH

Private
ViennaFrontier & Industrial Techhttps://circe.at/

Last Round

Grant

Sep 1, 2026

Total Funding Raised

$176,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Circe Biotechnologie GmbH is a biotechnology company that specializes in gas fermentation technology to convert methane and other gaseous feedstocks into sustainable single-cell protein and biodegradable bioplastics.

Sector

Frontier & Industrial Tech

Verticals

Biotechnology, Circular Economy, Sustainable Materials, Clean Manufacturing

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Data as a Service

AI Layer

Non-AI

Keywords

gas fermentationsingle-cell proteinSCPpolyhydroxyalkanoatesPHAmethanotrophic bacteriabiodegradable biopolymersbioplasticscircular bioeconomysustainable feedalternative proteinbioprocess engineeringmethane conversioncarbon capture utilizationCCU

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Circe Biotechnologie GmbH Comparables

Compare Circe Biotechnologie GmbH with similar companies based on industry and business-model similarity.

Circe Biotechnologie GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Econutri GmbH
84%
Aerbio
78%
Mango Materials
78%

Circe Biotechnologie GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 1, 2026
GrantJun 1, 2023
GrantMar 1, 2021

Key People

Founding team and executive leadership

Maximilian Lackner

Chief Technology Officer, Co-Founder

Founding Team

Circe Biotechnologie GmbH Investors

Notable investors and investment history

Circe Biotechnologie GmbH investors
InvestorRounds
FFG Austrian Research Promotion AgencyGrant
Circular Bio-based Europe Joint UndertakingGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors grew 565% MoM, from 236 to 1.6K.

Circe Biotechnologie GmbH Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Circe Biotechnologie GmbH Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Circe Biotechnologie GmbH's valuation, stock price, and market status.

Firmographic Details

HeadquartersVienna
Employee Range4
Year Founded2020
Last FundingSep 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.